Investors & Media - BrainStorm Cell Therapeutics

News

Press Releases

Month Year

Investor Alerts

Jul 5, 2018

BrainStorm Granted Japanese Patent for NurOwn®

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has received a Decision to Grant...
Jul 2, 2018

BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell and...
Jun 28, 2018

BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello

Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Joseph Petroziello as vice...
Jun 26, 2018

BrainStorm Provides Update on "Right to Try" Policy

Webcast and Conference Call at 8:30am Eastern Time Today NEW YORK and PETACH TIKVA, Israel, June 26, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of...
Jun 25, 2018

BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy

Conference Call and Live Webcast at 8:30am Eastern Time

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call tomorrow, June 26 th at 08:30am...
Jun 7, 2018

BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise...
Jun 1, 2018

BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing

Conference call and live webcast on June 7th at 8:15am EDT

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that the company will host a "Right-to-Try"...
May 30, 2018

BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate...
May 25, 2018

BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issues a statement following Congress passing the...
May 14, 2018

BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights

Call Today and Webcast @ 8:30am Eastern Time Today

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the first quarter ended...